Claudin 18.2 (CLDN18.2) expression prevalence, prognostication and clinical variables in gastric and gastroesophageal junction adenocarcinoma patient samples

被引：0
|
作者：
Sewastjanow, Matheus
Yamashita, Kohei
Iwata, Kenneth K.
Moran, Diarmuid
Elsouda, Dina
Pizzi, Melissa
Vicentini, Ernesto Rosa
Shanbhag, Namita
Ta, Anh
Waters, Rebecca
Chatterjee, Deyali
Ajani, Jaffer
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2141
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2141
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Prevalence of claudin 18.2 (CLDN18.2) and the association of biomarkers with clinical activity in patients with gastric or gastroesophageal adenocarcinoma (G/GEJa) treated with zolbetuximab.
    Moran, Diarmuid Martin
    Guerrero, Abraham
    Ueno, Yoko
    Park, Jung Wook
    Pavese, Janet
    Kaneko, Yuichiro
    Matsangou, Maria
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 466 - 466
  • [2] CLDN18.2 expression in gastric cancer for adoption in clinical practice
    Taffon, C.
    Vantaggi, S.
    Canalis, B.
    Di Matteo, F. M.
    Caputo, D.
    Perrone, G.
    VIRCHOWS ARCHIV, 2024, 485 : S505 - S506
  • [3] PREVALENCE OF CLAUDIN18.2 AND PD-L1 EXPRESSION IN CHINESE GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
    Mao, Linlin
    Yi, Wei
    Lin, Xu-Alan
    Gu, Ying
    Xia, Zhenzhong
    Qi, Chuan
    Shi, Michael
    Yu, Steven
    Qian, Xueming
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A115 - A115
  • [4] Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
    Kubota, Y.
    Kawazoe, A.
    Mishima, S.
    Nakamura, Y.
    Kotani, D.
    Kuboki, Y.
    Bando, H.
    Kojima, T.
    Doi, T.
    Yoshino, T.
    Kuwata, T.
    Shitara, K.
    ESMO OPEN, 2023, 8 (01)
  • [5] The cost-effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma
    Lai, Shufei
    Luo, Shaohong
    Huang, Qingwen
    Lin, Shen
    Huang, Xiaoting
    Xue, Honglin
    Cai, Yijun
    Xu, Xiongwei
    Weng, Xiuhua
    PHARMACOGENOMICS, 2024, 25 (5-6) : 249 - 257
  • [6] Prevalence of claudin 18.2 expression in gastric/gastroesophageal junction adenocarcinoma among patients in TranStar101 and TranStar102 clinical trials
    Shen, Li
    Mao, Carol
    Lin, Alan
    Gu, Ying
    Milata, Jenny
    Zhang, Lijuan
    Qi, Chuan
    Yao, Jenny
    Yu, Steven
    Yue, Changjun
    Shen, Lin
    Janjigian, Yelena
    Qian, Xueming
    Chang, Wen-I
    Germa, Caroline
    CANCER RESEARCH, 2024, 84 (06)
  • [7] Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer
    Kim, Seo Ree
    Shin, Kabsoo
    Park, Jae Myung
    Lee, Han Hong
    Song, Kyo Yong
    Lee, Sung Hak
    Kim, Bohyun
    Kim, Sang-Yeob
    Seo, Junyoung
    Kim, Jeong-Oh
    Roh, Sang-Young
    Kim, In-Ho
    JOURNAL OF GASTRIC CANCER, 2020, 20 (04) : 408 - 420
  • [8] Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18.2) in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma
    Lordick, F.
    Chao, J.
    Buxo, E.
    van Laarhoven, H. W. M.
    Lima, C. M. R.
    Lorenzen, S.
    Dayyani, F.
    Heinemann, V.
    Greil, R.
    Stienen, S.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S928 - S929
  • [9] A phase 1/2 study of LM-302, an anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate in patients with advanced gastric/gastroesophageal junction cancer.
    Bai, Chunmei
    Xue, Junli
    Zheng, Yi
    Sun, Meili
    Ying, Jieer
    Zhou, Fuxiang
    Yu, Yiyi
    Sun, Yuping
    Xing, Ligang
    Zhang, Yanqiao
    Wen, Jinhua
    Xiong, Jianping
    Wu, Heshui
    Yang, Xiuli
    Wan, Lixin
    Guo, Shiwei
    Zhao, Rusen
    Zhu, Zhizhen
    Gong, Zhihua
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Prevalence of CLDN18.2, HER2 and PD-L1 in gastric cancer samples
    Moran, D.
    Maurus, D.
    Rohde, C.
    Arozullah, A.
    ANNALS OF ONCOLOGY, 2018, 29
12345